Comparison of Cryopreserved Arterial Allografts Versus Heparin-bonded Vascular Grafts in Infragenicular Bypass for Chronic Limb Threatening Ischemia.


Journal

Annals of vascular surgery
ISSN: 1615-5947
Titre abrégé: Ann Vasc Surg
Pays: Netherlands
ID NLM: 8703941

Informations de publication

Date de publication:
Apr 2020
Historique:
received: 23 06 2019
revised: 12 09 2019
accepted: 12 09 2019
pubmed: 20 10 2019
medline: 1 9 2020
entrez: 20 10 2019
Statut: ppublish

Résumé

The purpose of this study was to compare cryopreserved arterial allograft (CAA) to heparin-bonded prosthesis (HBP) in infragenicular bypasses for patients with chronic limb-threatening ischemia (CLTI). This retrospective study took place in 2 university hospitals and included 41 consecutive patients treated for CLTI. In the absence of a suitable saphenous vein, an infragenicular bypass was performed using either CAA (24 cases) or HBP (17 cases). Kaplan-Meyer analysis compared primary and secondary patency and amputation-free survival rates. Binomial logistic regression analyzed risk factors for major amputation and thrombosis. The mean followup was 18.5 months (±14.3) in the CAA group, 17.6 (±6.1) in the HBP group. In the CAA group, primary and secondary patency rates at 12 months were 52% (±10.6) and 61% (±10.3), compared to 88% (±7.8) and 94% (±5.7) in the HBP group, respectively. The difference in patency rates was not statistically different (P = 0.27 and P = 0.28, respectively). The statistically significant factors of graft thrombosis were, a stage 4 from the WIfI classification (Wound Ischemia foot Infection) with a 6 times higher risk (P = 0.04), and a distal anastomosis on a leg artery with a 9 times higher risk of thrombosis (P = 0.03). Amputation-free survival rates at 18 months were similar between the groups (CCA: 75% (±9) versus HBP: 94% (±6), P = 0.11). Patients classified as WIfI stage 4 had 13 times higher odds to undergo major amputation than patients with WIfI stage 2 or 3 (95% CI, 1.16-160.93; P = 0.04). The intervention was longer in the CCA group of 74 min (278 min ± 86) compared to the HBP group (203 min ± 69). This difference was statistically significant (95% CI, 17.86-132.98), t(35) = 2.671, P = 0.01. CCA is not superior to HBP in infragenicular bypasses for CLTI, and may not be worth the extra cost and the longer operative duration.

Sections du résumé

BACKGROUND BACKGROUND
The purpose of this study was to compare cryopreserved arterial allograft (CAA) to heparin-bonded prosthesis (HBP) in infragenicular bypasses for patients with chronic limb-threatening ischemia (CLTI).
METHODS METHODS
This retrospective study took place in 2 university hospitals and included 41 consecutive patients treated for CLTI. In the absence of a suitable saphenous vein, an infragenicular bypass was performed using either CAA (24 cases) or HBP (17 cases). Kaplan-Meyer analysis compared primary and secondary patency and amputation-free survival rates. Binomial logistic regression analyzed risk factors for major amputation and thrombosis.
RESULTS RESULTS
The mean followup was 18.5 months (±14.3) in the CAA group, 17.6 (±6.1) in the HBP group. In the CAA group, primary and secondary patency rates at 12 months were 52% (±10.6) and 61% (±10.3), compared to 88% (±7.8) and 94% (±5.7) in the HBP group, respectively. The difference in patency rates was not statistically different (P = 0.27 and P = 0.28, respectively). The statistically significant factors of graft thrombosis were, a stage 4 from the WIfI classification (Wound Ischemia foot Infection) with a 6 times higher risk (P = 0.04), and a distal anastomosis on a leg artery with a 9 times higher risk of thrombosis (P = 0.03). Amputation-free survival rates at 18 months were similar between the groups (CCA: 75% (±9) versus HBP: 94% (±6), P = 0.11). Patients classified as WIfI stage 4 had 13 times higher odds to undergo major amputation than patients with WIfI stage 2 or 3 (95% CI, 1.16-160.93; P = 0.04). The intervention was longer in the CCA group of 74 min (278 min ± 86) compared to the HBP group (203 min ± 69). This difference was statistically significant (95% CI, 17.86-132.98), t(35) = 2.671, P = 0.01.
CONCLUSIONS CONCLUSIONS
CCA is not superior to HBP in infragenicular bypasses for CLTI, and may not be worth the extra cost and the longer operative duration.

Identifiants

pubmed: 31629123
pii: S0890-5096(19)30840-4
doi: 10.1016/j.avsg.2019.09.003
pii:
doi:

Substances chimiques

Anticoagulants 0
Coated Materials, Biocompatible 0
Heparin 9005-49-6

Types de publication

Comparative Study Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

33-42

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Audrey Hirth-Voury (A)

Departement of Vascular Surgery, Centre Hospitalier Universitaire de Nice, Nice, France; Université Côte d'Azur, Medical school, Nice, France.

Nicolas Massiot (N)

Departement of Vascular Surgery, Centre Hospitalier Universitaire de Reims, Nice, France; Université de Reims Champagne-Ardenne, Medical school, Reims, France.

Emmanuelle Giauffret (E)

Université Côte d'Azur, Medical school, Nice, France; Vascular Laboratory, Centre Hospitalier Universitaire de Nice, Nice, France.

Charlotte Behets (C)

Departement of Vascular Surgery, Centre Hospitalier Universitaire de Reims, Nice, France; Université de Reims Champagne-Ardenne, Medical school, Reims, France.

Ambroise Duprey (A)

Departement of Vascular Surgery, Centre Hospitalier Universitaire de Reims, Nice, France; Université de Reims Champagne-Ardenne, Medical school, Reims, France.

Réda Hassen-Khodja (R)

Departement of Vascular Surgery, Centre Hospitalier Universitaire de Nice, Nice, France; Université Côte d'Azur, Medical school, Nice, France.

Elixène Jean-Baptiste (E)

Departement of Vascular Surgery, Centre Hospitalier Universitaire de Nice, Nice, France; Université Côte d'Azur, Medical school, Nice, France.

Nirvana Sadaghianloo (N)

Departement of Vascular Surgery, Centre Hospitalier Universitaire de Nice, Nice, France; Université Côte d'Azur, Medical school, Nice, France. Electronic address: sadaghianloo.n@chu-nice.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH